<DOC>
	<DOC>NCT00632216</DOC>
	<brief_summary>The study in the labeled and real conditions of prescription of Actonel will investigate the satisfaction of patients with its new formulation: 35 mg Once A Week. The study will also measure response rates in CTX (the C-telopeptide of type I collagen) at baseline and after 12 weeks of treatment with risedronate 35 mg Once A Week.</brief_summary>
	<brief_title>A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Postmenopausal outpatients women &gt; 55 and &lt; 70 years who have a clinical presentation appropriate for treatment of established osteoporosis based on the investigator's clinical judgment (a Tscore for BMD (DEXA) of lumbar spine or femoral neck less than or equal to 2.5 from an assessment performed at screening or within 12 months prior to the screening visit or evidence of previous vertebral fracture). History of Cancer: Basal Cell or Squamous Cell carcinomadocumented 6month remission. Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>